Description: Amid macroeconomic uncertainty, proactive lapse management is becoming a growing strategic focus for Life and Annuity carriers. Interest rates have been increasing rapidly during the last eighteen months and insurers, especially annuity writers, have started to see higher lapses and withdrawals. After a prolonged low interest period, many insurers will have to (re)build capabilities to enable proactive lapse management.

Description: The famous 80/20 rule in data science states that only 20% of your time working with data is spent driving insightful business analytics. The rest of your time is spent trying to query, clean and organize your data. Even with this knowledge, the majority of actuarial training/focus is on the 20 percent. This session takes a different approach, focusing solely on speeding up your work on the other 80 percent. Practical examples will be part of a code walkthrough in R.

Description: Regression to the mean (RTTM) is inflating your health care intervention evaluations if you are not carefully managing it's omnipresent and significant impact RTTM is the statistical phenomenon which arises when comparing sequential data points when an initial observation is extreme or an outlier, and states that with no other intervention, future observations will be closer to the average. Members who had high costs last year will, on average, have lower costs this year, even in the absence of any intervention or clinical program, simply by 'regressing' to the mean. This means that if your clinical programs are simply targeting members who had adverse medical experience last year, you’re targeting the wrong people. And if your savings methodologies are simply last year’s costs minus this year’s costs, the savings are inflated. By attending this session, you will be able to identify situations where RTTM will be a significant factor, how to eliminate it's impact when performing retrospective evaluations, how to identify prospects for clinical intervention with RTTM in mind, and more.

Description: The SOA has conducted a mortality study covering deferred annuities, both fixed and variable. This is a brand new area of analysis for the SOA's Individual Annuity Experience Committee and should be of critical interest to the industry. Previous industry annuitant mortality studies have focused on payout annuities, as well as the specialized structured settlement annuity market. Traditionally, mortality had not been seen as a critical assumption for deferred annuities. As the products have evolved over time, especially with the popularity of enhanced death benefits for variable annuities and guaranteed living benefits for both variable and fixed annuities, mortality has taken on increased importance. The results of this study have recently taken on even greater significance, as regulators are seeking mortality assumptions for the standard projection scenario for VM-22 (fixed annuities), as well as a potential update to those assumptions in VM-21 (variable annuities). By attending the session, you will: - Understand how deferred annuitant mortality compares with established annuitant mortality tables. Note that annuitant mortality tables, including the most recent 2012 tables, were developed based on payout annuitant mortality experience. - Become aware of the differences in mortality experience between fixed and variable annuities. - Gain insights into the effect of various guaranteed benefits on anti-selection and subsequent annuitant mortality, both for death benefits and living benefits. - Understand the durational aspects of emerging mortality experience, particularly for deferred annuities with guaranteed benefits.

Description: Anti-obesity medications have been met with reluctance from payers and employee benefits consultants who often lack analogs or empirical data to estimate the cost impact of new therapies coverage. Health plans considering coverage of anti-obesity medications will need to assess and manage the potential costs of covering these new therapies in context of their overall obesity management strategy, including coverage of nutrition counseling, weight management, and bariatric surgery.

Description: This session will bring together public health care leaders in COVID-10 vaccine delivery from both the U.S. and the UK to discuss and compare operational implications of the COVID-19 vaccine rollout in their countries, and how those programs ultimately affected hospitalization utilization and mortality rates for members of their communities.

Description: Become informed about the approach and adverse effects of the regulation of third parties and advance consent by the proposed NAIC Consumer Privacy Protection Model Law #674. You will hear an explanation of the regulation of third parties through their contracts with insurers. Learn specifics on the negative effect on companies contracting with third parties. Find out more about the requirement for advance consent for use of personal data for actuarial and marketing studies, and hear two potential solutions .At the conclusion of this session, you should be able to explain concerns about contracting with third parties for external data under the Model Law and learn potential solutions to using personal data for actuarial and marketing studies.

Description: Report on survey designed to get feedback on underwriting guidelines, requirements, assumptions and practices used in assessment of older age applicants.

Description: A reference document which describes the table development process.

Description: The definition of simplified issue business developed by the Society of Actuaries and the Academy of Actuaries.